Recombinant Human IL-13 R alpha 2 His-tag, CF

Name: Recombinant Human IL-13 R alpha 2 His-tag, CF
Brand: R&D Systems
SKU: 11562-IR

R&D Systems, part of Bio-Techne | Catalog # 11562-IR

Submit a review

Product Datasheet / COA / SDS

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Background
Product Documents
Specific Notices

Key Product Details

R&D Systems HEK293-derived Recombinant Human IL-13 R alpha 2 His-tag (11562-IR)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

HEK293

Accession #

Q14627.1

Conjugate

Unconjugated

Applications

Bioactivity

View all IL-13 R alpha 2 Proteins and Enzymes »

Product Specifications

N-terminal Sequence Analysis

Pro 43

Predicted Molecular Mass

36 kDa

SDS-PAGE

53-58 kDa, under reducing conditions

Scientific Data Images for Recombinant Human IL-13 R alpha 2 His-tag, CF

Recombinant Human IL-13 R alpha 2 His-tag Protein Bioactivity.

Recombinant Human IL-13 R alpha 2 His-tag Protein (Catalog # 11562-IR) inhibits Recombinant Human IL-13 (213-ILB) induced proliferation in the TF-1 human erythroleukemic cells. The ED₅₀ for this effect is 4.00-60.0 ng/mL.

Recombinant Human IL-13 R alpha 2 His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant Human IL-13 R alpha 2 His-tag Protein (Catalog # 11562-IR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 53-58 kDa, under reducing conditions.

Formulation, Preparation and Storage

11562-IR

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 200 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.

Background: IL-13 R alpha 2

Interleukin‑13 Receptor alpha 2 (IL‑13 R alpha2), also known as IL‑13 binding protein, and CD213a2, is a widely expressed 55 kDa cytokine receptor that plays an important role in the Th2‑polarized immune responses characteristic of a variety of pathologies, including parasitic infections and allergic asthma (1, 2). Mature human IL‑13 R alpha2 consists of a 317 amino acid (aa) extracellular domain with three fibronectin type‑III domains, a WSxWS motif, a 20 aa transmembrane segment, and a 17 aa cytoplasmic domain (3). Within the ECD, human IL‑13 R alpha2 shares 64% and 62% aa sequence identity with mouse and rat IL‑13 R alpha2, respectively. In both mouse and human, a 40 kDa‑50 kDa soluble form of IL‑13 R alpha2 can be generated by MMP‑8 mediated shedding in vitro (4). Although this is assumed to occur in vivo in mouse, there is no evidence that shedding occurs in human (5‑7). In mouse, alternative splicing also leads to sIL‑13 R alpha2, but again, this phenomenon apparently does not occur in human (6‑7). Thus, the biological effects of human IL‑13 R alpha2 would appear to be mediated exclusively by membrane IL‑13 R alpha2 (7). The biological effects of IL‑13 and IL‑4 are closely related in part due to a shared receptor system. IL‑13 binds to IL‑13 R alpha1 which then forms a signaling complex with IL‑4 R alpha (8, 9). IL‑13 R alpha2 functions as a decoy receptor by binding and internalizing IL‑13 and preventing it from signaling through the IL‑13 R alpha1/IL‑4 R alpha complex (3, 10). IL‑13 R alpha2 can also block IL‑4 induced responses by inhibiting IL‑4 bound IL‑13 R alpha1/IL‑4 R alpha receptor complexes even though it does not itself bind IL‑4 (11, 12). Aside from its decoy function, IL‑13‑activated IL‑13 R alpha2 directly promotes the development of tissue fibrosis by inducing the transcription of TGF‑ beta (13). Presumably, any human soluble IL‑13 R alpha2, if it exists, will retain its ligand binding capability and attenuate responses to IL‑13 but not to IL‑4 (11, 14). The up‑regulation of transmembrane during Th2‑biased immune responses limits the extent of those responses (15‑17).

References

Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
Caput, D. et al. (1996) J. Biol. Chem. 271:16921.
Chen, W. et al. (2008) J. Allergy Clin. Immunol. 122:625.
O’Toole, M. et al. (2008) Clin. Exp. Allergy 38:594.
Chen, W. et al. (2009) J. Immunol. 183:7870.
Kasaian, M.T. et al. (2011) J. Immunol. 187:561.
Andrews, A.-L. et al. (2006) J. Immunol. 176:7456.
Zurawski, S.M. et al. (1995) J. Biol. Chem. 270:13869.
Donaldson, D.D. et al. (1998) J. Immunol. 161:2317.
Andrews, A.-L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
Rahaman, S.O. et al. (2002) Cancer Res. 62:1103.
Fichtner-Feigl, S. et al. (2006) Nat. Med. 12:99.
Zhang, J.G. et al. (1997) J. Biol. Chem. 272:9474.
Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
Morimoto, M. et al. (2009) J. Immunol. 183:1934.
Zheng, T. et al. (2008) J. Immunol. 180:522.

Long Name

Interleukin 13 Receptor alpha 2

Alternate Names

CD213a2, IL-13Ra2, IL13R alpha 2, IL13RA2

Entrez Gene IDs

3598 (Human); 16165 (Mouse)

Gene Symbol

IL13RA2

UniProt